Hutchmed (China) Limited Total Voting Rights (9477G)
30 Juillet 2021 - 10:30AM
UK Regulatory
TIDMHCM
RNS Number : 9477G
Hutchmed (China) Limited
30 July 2021
Total Voting Rights
Hong Kong, Shanghai, & Florham Park, NJ - Friday, July 30,
2021: HUTCHMED (China) Limited (" HUTCHMED" ) (Nasdaq/AIM: HCM,
HKEX: 13) hereby notifies the market that as at July 30, 2021, the
issued share capital of HUTCHMED consisted of 864,115,660 ordinary
shares of US$0.10 each, with each share carrying one right to vote
and with no shares held in treasury.
The above figure of 864,115,660 may be used by shareholders as
the denominator for the calculations by which they could determine
if they are required to notify their interest in, or a change to
their interest in, HUTCHMED under the Financial Conduct Authority's
Disclosure Guidance and Transparency Rules.
For illustrative purposes only, the 864,115,660 ordinary shares
would be equivalent to 864,115,660 depositary interests (each
equating to one ordinary share) which are traded on AIM or, if the
depositary interests were converted in their entirety, equivalent
to 172,823,132 American depositary shares (each equating to five
ordinary shares) which are traded on Nasdaq.
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative,
commercial-stage, biopharmaceutical company. It is committed to the
discovery, global development and commercialization of targeted
therapies and immunotherapies for the treatment of cancer and
immunological diseases. A dedicated organization of over 1,300
personnel has advanced eleven cancer drug candidates from in-house
discovery into clinical studies around the world, with its first
three oncology drugs now approved and marketed. For more
information, please visit: www.hutch--med.com or follow us on
LinkedIn.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Media Enquiries
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Europe - Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779
545 055 (Mobile)
HUTCHMED@fticonsulting.com
Asia - Zhou Yi, Brunswick +852 97 83 6894 (Mobile)
HUTCHMED@brunswickgroup.com
Nominated Advisor
Atholl Tweedie / Freddy Crossley, Panmure Gordon (UK)
Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRGZGZNZLVGMZM
(END) Dow Jones Newswires
July 30, 2021 04:30 ET (08:30 GMT)
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juil 2024 à Août 2024
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Août 2023 à Août 2024